OC 21.4 Durable efficacy and safety in responders: 5-Year post hoc end-of-study analysis of etranacogene dezaparvovec in the phase 3 HOPE-B trial in patients with severe/moderately severe haemophilia B

Cedric R.J.R. Hermans, Emily M. Symington, Michael Recht, Nigel Key, Giancarlo Castaman, Wolfgang Miesbach, Sandra Le Quellec, Nathalie W. D. Jansen 等 11 位